• Satsuma Pharmaceuticals flagged two clinical-program abstracts accepted for presentation at the American Headache Society meeting on June 4-7, 2026.
• Results will be presented on June 4, covering a comparison of STS101 DHE nasal powder exposure versus nasal spray and injectable DHE options.
• A separate analysis will compare adverse-event profiles across FDA-approved intranasal acute migraine treatments, positioning STS101 against existing nasal competitors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satsuma Pharmaceuticals Inc. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.